Novel Thrice-Weekly Isoniazid plus Rifapentine Short-Course Regimen for the Treatment of Latent Tuberculosis Infection in a Murine Model  

作　　者：Qiaoling Ruan Jingyu Zhou Shufeng Weng Lingyun Shao Wenhong Zhang 

机构地区：[1]Department of Infectious Diseases,Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response,National Medical Center for Infectious Diseases,Huashan Hospital,Shanghai Medical College,Fudan University,Shanghai 200040,China [2]State Key Laboratory of Genetic Engineering,Institute of Genetics,School of Life Science,Fudan University,Shanghai 200438,China [3]Shanghai Sci-Tech Inno Center for Infection&Immunity,Shanghai 200052,China.

出　　处：《Infectious Diseases & Immunity》2024年第3期138-141,共4页感染性疾病与免疫（英文）

基　　金：supported by National Natural Science Foundation of China(82271794,82302533);Shanghai Municipal Science and Technology Major Project(HS2021SHZX001).

摘　　要：1.Introduction Tuberculosis(TB),caused by Mycobacterium tuberculosis,remains a leading cause of death among infectious diseases worldwide.Latent tuberculosis infections(LTBI)contribute to the global burden of TB disease.TB preventive treatment(TPT)is a key intervention to achieve the End TB Strategy targets.The World Health Organization recommends LTBI treatment regimens,including 6 or 9 months of once-daily isoniazid(INH,H),4 months of once-daily rifampin(RIF,R),3 months of once-weekly rifapentine(RPT,P)plus INH(3HP),3 months of once-daily RIF plus INH,or 1 month of daily RPT plus INH(1HP).Clinicians and individuals with LTBI may be reluctant to implement TPT due in part to concerns regarding adherence to the long treatment duration and drug toxicity of the currently recommended LTBI treatment regimens.Shorter,better-tolerated,and cost-effective TPT regimens are highly desirable.Rifapentine is a long-acting rifamycin,and rifamycin-based regimens are now the preferred LTBI treatment because they have similar or better efficacy and higher completion rates due to their shorter duration.Based on our experiences with TPT practice among Chinese people with silicosis,we found that the 3HP regimen was not well tolerated due to an unexpectedly high frequency of adverse events(AEs)(70.4%)and grade 3 or 4 AEs(7.9%),especially the high incidence of flu-like systemic drug reactions(SDRs)(10.8%).

关 键 词：REGIMEN TUBERCULOSIS TREATMENT 

分 类 号：R52[医药卫生—内科学]